SITEMAP

• Science
  • Cutting Edge Science
  • Inspiration and Innovation
  • Asthma
    • Cutting Edge Science
      • 2021
        • About Type 2 Inflammation – Asthma
      • Innovation
        • What is your experience with Dupixent in your practice?
        • What gives you confidence that Dupixent improves patients’ quality of life?
      • 2022
        • Consider Dupixent for Asthmatic patients with high EOS
        • Consider Dupixent for Asthmatic patients with OCS use
        • Discover a solution to control mixed Eosinophilic and Allergic Asthma
        • Dupixent® (dupilumab) Mechanism of Action
      • 2023
      • 2024
        • Adult Asthma Remission
        • Airway Hyperresponsiveness
          in Asthma
        • The Vital Role of Lung Function in Asthma Care
        • Severe Asthma Biomarker's
        • Sever Asthmatic patients with OCS
        • Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms
        • Fractional exhaled nitric oxide (Feno)
      • 2025
        • FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
        • Mucus Plugging Is a Key Component of Remodeling
          in Asthma, Leading to Fixed Airway Obstruction
        • VESTIGE study
        • VESTIGE Trial Results: Dupilumab in Type 2 Asthma
        • Pediatric Management
        • Assessing Pediatric Lung Function
        • The Role of Mucus Plugging in Asthma and Its Clinical Burden
        • Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease
      • 2026
        • IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION
        • IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
        • Dupilumab improves clinical outcomes in patients with severe asthma compared to other biologics
        • LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Eosinophilic (≥500 cells/µL) and Allergic Asthma Subgroups
        • LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Type 2 Asthma Patients on High-Dose ICS
        • LIBERTY ASTHMA TRAVERSE Trial: Long-Term Safety and Efficacy of Dupilumab in Moderate-to-Severe Asthma
        • LIBERTY ASTHMA QUEST Trial: Dupilumab Evidence Summary in Moderate-to-Severe Uncontrolled Asthma
  • Atopic Dermatitis
    • Cutting Edge Science
      • 2021
      • Innovation
      • 2023
      • 2024
      • 2024
  • Bullous Pemphigoid
    • 2025
      • What is Bullous Pemphigoid
      • Patient morbidity and mortality in BP
      • Pathophysiology of Bullous Pemphigoid
      • Treatments and challenges for bullous pemphigoid
      • Considerations for bullous pemphigoid management
      • Bullous Pemphigoid Burden of Disease and Diagnosis
    • 2025
      • Bullous Pemphigoid Mechanism of Disease Animation Storyboard
  • Cardiovascular
    • Atherothrombosis
      • Cutting Edge Science
        • Innovation
          • 2022
          • 2023
        • 2022
        • 2023
    • Dyslipidemia
      • Cutting Edge Science
        • 2021
        • Innovation
          • Identifying and Treating Patients with High Lipidaemia Risk Post-ACS
          • 2022
        • 2022
    • Hypertension
      • Cutting Edge Science
        • 2023
    • Thrombosis
      • Cutting Edge Science
        • 2021
        • Innovation
          • 2022
          • 2023
        • 2022
          • Benefit of Prophylaxis for High-Risk Surgical Patients
          • Global use of RAM and Thromboprophylaxis in hospitalized patients
          • Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
          • Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
          • Maternity Clot Risk Model to Predict Women at Risk of VTE
        • 2023
    • Cutting Edge Science
      • 2021
      • Innovation
  • Chronic Obstructive Pulmonary Disease
    • Cutting Edge Science
      • Innovation
      • 2023
      • 2025
        • Chronic Obstructive Pulmonary Disease (COPD): Disease Burden and Heterogeneity
        • (COPD): Disease Burden and Heterogeneity
        • Type 2 Inflammation in the Pathophysiology of the Lower Airways
        • Clinical Indicators of COPD: A GOLD Guidelines Review
      • 2026
        • GOLD 2026 Report: Key Updates for COPD Management
        • Dupilumab Efficacy Across Baseline Eosinophil Counts in COPD
  • Diabetes
    • Cutting Edge Science
      • 2021
      • Innovation
        • Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
        • The SoliRam observational study
        • Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
        • EVOLUTION: RWE from Saudi Arabia
        • EMPOWER Study in Saudi Arabia
        • 2022
      • 2022
        • A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
        • Closed-loop insulin delivery during exercise in people with T1DM
        • Diabetes management during Ramadan
        • Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
        • Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
        • Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
      • 2023
      • 2024
        • Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
        • The Evolving Role of Treatment and Technology in Diabetes Care
        • Time-in-Range: A Key Determinant of Quality of Life
        • SoliD: Redefine Treatment Paradigm Post-OAD
        • Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
        • The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
        • Why to screen for Autoimmune T1D
        • How to screen for Autoimmune T1D
        • The burden of Autoimmune T1D
        • Understanding Autoimmune T1D disease & Different Stages
      • 2024
        • New Horizon in management of high-risk patients with Diabetes
        • Effective Treatment Simplification
  • Eosinophilic-Esophagitis
    • Cutting Edge Science
      • 2022
        • Understanding eosinophilic esophagitis (EoE)
      • 2024
        • EOE Pediatric - Unmasking the Hidden Symptoms
        • Importance of assessing key disease domains in EOE
      • 2024
        • EoE Pathophysiology
        • EoETaly Guidelines Part-1
        • EoETaly Guidelines Part-2
        • Pediatric EoE: Indicators for Early Diagnosis and Intervention
        • Adaptive Eating Behaviors in EoE
        • Dupilumab in Pediatric EoE: Phase 3 KIDS Study Results
      • 2026
        • Dupilumab is Efficacious Regardless of Endoscopic Phenotype: Post Hoc Analysis of the LIBERTY EoE TREET Study
        • Dupilumab Maintained Histologic and Endoscopic Improvements During the Open-Label Extension Period of the EoE KIDS Study
      • Innovation
  • Multiple Myeloma
    • Cutting Edge Science
      • 2022
        • Experts Perspective
        • Myeloma Facts
        • True Cost of Multiple Myeloma
        • Patients Factors & Impacts
      • 2023
      • 2026
        • Transform Myeloma
  • Multiple Sclerosis
    • Cutting Edge Science
      • 2022
        • MS Updates
        • Why has our brain suddenly become of interest?
        • Cognitive decline – The invisible burden of MS?
      • Innovation
        • 2021
        • 2022
        • 2025
          • Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity
          • Inside MS: Explore how BTK drives immune cell activation and CNS damage
      • 2023
      • 2024
        • Learning aRMMs
      • 2025
        • Tolebrutinib Direct Effects on Myeloid Cells in PwMS
      • 2026
        • Understanding PIRA in MS: An Overview with Dr. Barry Singer
        • Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer
        • Understanding 6‑Month CDP in MS: An Overview with Dr. Barry Singer
        • MS Pulse Reels - MS Monitoring in Practice | Turning Tracking into Action
        • MS Pulse Reels - How to Track MS | Acknowledge, Assess, Advocate
        • MS Pulse Reels - See the Bigger Picture: Why Tracking Matters
    • Smoldering Neuroinflammation
    • MS Pulse Reels
  • Nasal Polyps
    • Cutting Edge Science
      • 2021
      • 2022
        • Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation
      • 2023
        • What can biologic treatment do for patients with CRS with nasal polyps?
        • How does Dupixent help recover smell?
        • NPS improvement with Dupixent over time
        • "It really has changed the way I manage our patients"
        • “Smell—we call it the Cinderella of the senses"
        • What does patient empowerment mean for your treatment plan?
        • You can imagine more than 90% of CRSwNP patients losses their ability's of smell
        • Hear from an expert on would you consider a biologic for a Surgery-naïve Patient with CRS with Nasal Polyps?
        • Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?
        • Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.
        • Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment
      • 2024
        • Daily Burden of CRSwNP
      • 2025
        • IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP
        • Loss of Smell Is a Key Symptom in CRSwNP
        • Loss of Smell Improvement in Patients With CRSwNP
        • EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP
        • CRSwNP EVEREST
  • Neurological Disorders
    • Cutting Edge Science
      • 2022
      • 2023
      • Innovation
  • Prurigo-Nodularis
    • Cutting Edge Science
      • 2022
        • Mechanism of Prurigo Nodularis Disease
        • There is significant unmet need in the management of PN¹
        • Prurigo Nodularis Is A Distinct, Chronic, Neural And Immune- Mediated Skin Disease Characterized By Intense Itch And Nodular Lesions1
        • Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1
      • 2022
        • Practical Approach in Understanding PN Pathophysiology
        • The Pathophysiology of Prurigo Nodularis
  • Rare Diseases
    • Cutting Edge Science
      • 2021
      • Innovation
        • Bone Monitoring Guidelines in Gaucher Disease Video
        • Professor Moeen Al Sayed video on ASMD
        • Professor Tawfeq Ben Omran video on ASMD
        • Better care for Fabry
        • Gaucher disease awareness month video
        • 2022
          • The Role of Pediatrician in Gaucher Disease
      • 2022
        • How do you know if you or a loved one has ASMD?
        • How is ASMD inherited?
        • MPSI – Endocrinology Case Study
        • What is ASMD?
      • 2023
        • Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
        • Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
        • Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
        • Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
        • Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
        • Gaucher
      • 2024
        • BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
        • ROLE OF ECG IN DIFFERENTIAL DIAGNOSIS OF ANDERSON–FABRY DISEASE WITH HCM
        • DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
        • Pompe Care Podcast Series
        • Navigating the Pompe Disease Journey
        • Impact of symptoms and risk of ASMD on patients and caregivers
        • Differential diagnostics for ASMD in patients suspected to have GD
        • Consensus Guidelines for the Clinical Management of ASMD
        • What Are the Signs and Symptoms of ASMD?
        • ASMD
        • Legacy Video for Rare Disease Academy
        • Uncover ASMD and GAUCHER
      • 2025
        • Every Moment Matters: Navigating Diagnosis of Fabry Disease
        • Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)
        • Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results
        • Understanding Gaucher Disease Type 3
      • 2026
        • Gaucher Mechanism of Disease
        • Gaucher Neurology Diagnosis Support
        • Gaucher Haematology Diagnosis Support
        • Gaucher Biochemistry Diagnosis Support
        • Tolerability of Accelerated Agalsidase Beta Infusions in Fabry Disease: The SHORTEN Study Analysis
        • From Registry to Reality: Reduced Stroke Incidence with Agalsidase Beta in Fabry Disease
        • Fabry Disease in Cardiology Practice: From Red Flags to Diagnosis
        • When the Heart, Kidneys, and Nerves Intersect
        • Renal Outcomes After Switching to Agalsidase Beta: A Single-Center Analysis
        • Structured Monitoring for Early Detection of Fabry Progression
        • Pompe Care Podcast Series 2
        • What has been your experience with switching patients from alglucosidase alfa to avalglucosidase alfa?
        • What makes avalglucosidase alfa different from alglucosidase alfa in terms of clinical efficacy and patient outcomes?
        • How can you see changing the lives of patient starting taking Nexviazyme and if you can share from your experience couple of patient stories that realy impacted positively from staring the treatment for Pompe disease?
        • Thank You!
        • Pompe Care Podcast Series 3
        • What factors influence your decision to switch a patient from alglucosidase alfa to avalglucosidase alfa?
        • How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?
        • Have you observed any significant differences in treatment outcomes between these two therapies in your local practice?
        • What challenges do clinicians face in monitoring in disease progrission and response to therapy?
    • Gaucher
      • Cutting Edge Science
    • Fabry
      • Cutting Edge Science
  • Vaccines
    • Influenza
      • Cutting Edge Science
        • 2021
        • Innovation
          • Sanofi Pasteur at Glance
          • Sanofi Pasteur at Glance
        • 2022
        • 2023
          • Flu and Vaccination
          • Flu in High Risk Population
    • RSV
      • Cutting Edge Science
        • Innovation
        • 2023
          • RSV
          • Burden of Disease
          • RSV History
          • Rattle
          • All Infant Protection
        • 2024
          • RSV Burden in Infants
          • Saudi initiatives on Bronchiolitis Recommendations
        • 2025
          • RSV Burden in Jazan
          • Beyond High-Risk: Expanding RSV Protection for Newborns and Infants
          • New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention
          • Nirsevimab RWD Metanalysis
          • Kuwait taking the lead in RSV protection for all infants in the Middle east
          • Ensuring overall RSV prevention in every individual Dr. Alia Podcast
          • Nirsevimab FAQs
          • Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia: A MNGHA Facilities Analysis
          • Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons
        • 2026
          • RWE data on Nirsevimab and RSV preF vaccine
          • Expanding RSV Protection in Kuwait: New National Directives for Monoclonal Antibody Use
          • Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study
          • RSV Prevention Guidelines in UAE
          • An overview of the latest Saudi evidence presented at ESPID 2026.
          • An overview of the latest Saudi evidence presented at ESPID 2026.
          • Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia
    • Mass Gathering
      • Cutting Edge Science
        • 2025
          • Infectious Disease During Mass Gathering
  • Rhinology
    • Cutting Edge Science
      • Dupilumab for Patients with AFRS
• Patient Support
  • Patient Support Articles
  • Atopic Dermatitis
    • 2022
  • Cardiovascular
  • Diabetes
    • Tools and Resources
      • Clinical and economic value of Soliqua - Pharmacist perspective
      • Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan
    • 2022
      • Dose adjustment of insulins and other medications during Ramadan
    • 2021
  • Rare Diseases
  • Vaccines
    • RSV
• Products
  • Aubagio®
    • Aubagio vs Ofatumumab
  • Beyfortus®
    • International Recommendation
      • Nirsevimab International Recommendation
    • Conferences
      • Implementing Beyfortus successfully
      • Beyfortus®, an innovative immunization
      • Beyfortus in Action ECMMID
      • 2024 RSV International Congress - ESPID
      • 2024 RSV International Congress ECMMID
    • Real World Evidence
      • Implementing Beyfortus successfully (ES)
      • Implementing Beyfortus successfully (FR)
      • Implementing Beyfortus successfully (US)
      • Beyfortus in Action
      • Real World Evidence Impact of universal immunization with Nirsevimab
    • Clinical Experience
      • Nirsevimab : Clinical Experience
  • Cerezyme®
  • Clexane®
    • Surgical Patients
    • Hemodialysis
  • Dupixent®
    • Atopic Dermatitis
    • Dupixent Asthma
    • Nasal Polyps
    • Dr. Ayman Alnaeem’s Very First Dupixent Patient Experience
    • A Message to You from Dr. Ayman AlNaeem
    • How Dupixent Changed Dr. Ayman AlNaeem’s Approach in AD Treatment
    • The Burden of AD through Dr. Ayman Alnaeem’s Expertise/eyes
    • The Burden of AD by Dr. Paula Nelson
    • Dr. Paula Nelson’s Very First Dupixent Patient Experience​
    • Dr. Paula’s insights on treating AD patients with Dupixent
  • Fabrazyme®
    • Quantifying the Effect of Fabrazyme
    • Canadian Fabry Disease Initiative
    • Long Term Renal Function
  • Lemtrada®
  • Myozyme®
  • Praluent®
    • Praluent®
      • LDL-C Control
      • LDL-C Control
      • LDL-C Control
      • LDL-C Control
    • It’s Praluent of Course
      • MACE Reduction
      • Mortality Reduction
      • Patient Friendly
      • Ticks All the Boxes
  • Soliqua®
    • For a Peaceful Ramadan
    • Soliqua SoliD®
    • Soliqua Easy Start®
    • Soliqua Guidelines®
    • Soliqua Data Set®
    • Soliqua Simplicity®
    • Soliqua Safety®
    • Soliqua®
    • Reimbursement
    • Meet The Expert
    • Soliqua Unmet Needs Video
    • Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
    • Limitations of Premixed Insulin
  • Toujeo®
    • Toujeo for a Peaceful Ramadan
    • Wall of Evidence
    • Toujeo T1DM
      • OneCare
      • Edition Junior
      • UltraFlexi-1
      • Type-1 Meta Analysis
      • Guidelines
    • Toujeo T2DM
      • Deliver-G
      • Guidelines
    • How to Start
    • Toujeo Innovation
      • Toujeo Upgrade to Win
    • Timely insulin initiation to limit disease progression
    • Meet the Expert
    • Second generation basal insulin in advancing T2D therapy
    • Always On
      • How to Start People with Diabetes to Toujeo
      • Bridging the Glycemic Gap- Timely Transition from OADs to Toujeo
      • Evolving Basal Insulin Therapy- From 1st Gen to 2nd Gen
      • The Kidney-Diabetes Connection- Clinical Use of Toujeo in Dual Diagnosis
      • Toujeo vs Degludec- Clinical Insights from the BRIGHT study for Insulin selection
      • Toujeo and GLP1s- Optimising Glycemic Control in Uncontrolled T2D
      • New Findings on Toujeo® for T2D Management Following Dual GIP-GLP-1 RA Therapy
  • Xatral®
• Events
  • Cardiovascular
    • 2021
      • VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
    • 2022
    • 2023
  • Diabetes
    • 2021
    • 2022
      • Innovation of Iglarlexi in Intensification
      • Ultimate Need for Intensification
      • Innovation of Iglarlexi in Intensification
    • 2023
      • Amaryl Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
      • Safe & Smart - Dr. Kalra
      • Safe & Smart - Dr. Khudhair
      • Safe & Smart - Dr. Nabil
      • Safe & Smart - Dr. Salah
    • 2024
      • Dia-Tour: Navigating New Destinations in Diabetes Management
  • Rare Diseases
    • 2022
    • 2024
      • Fabry Monitoring Matters Webinar Series
    • 2026
      • Rare Disease Academy 2.0/ Spotting the Signs: A guide to Early Diagnosis and a Timely Refferals
  • Vaccines
    • 2022
  • Multiple Sclerosis
    • 2022
    • 2023
      • The Underlying Biology of Neuroinflammation
    • 2026
      • Advancing the Standard of Care: Addressing Progression in MS
  • Prurigo Nodularis
    • 2022
  • Anti-Infectives
    • 2022
    • 2023
  • Neurological Disorders
    • 2023
      • World Epilepsy Day Podcast Ep. 1
      • World Epilepsy Day Podcast Ep. 2
      • World Epilepsy Day Podcast Ep. 3
    • 2026
      • MS pulse - Tracking the hidden drivers of MS progression
    • 2022
  • Atopic Dermatitis
    • Type II Summit 2025
• Cookie Policy
• Legal Notice
• Privacy Policy
• Sanofi in News
  • 2022
    • Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom
    • Ministry of Health organizes "KiDS" program at Expo 2020 Dubai to promote diabetes awareness at schools
• Search
• Registration